Bright Minds Biosciences (DRUG) EPS (Weighted Average and Diluted) (2023 - 2024)
Bright Minds Biosciences (DRUG) reported EPS (Weighted Average and Diluted) of $4961.0 for Q4 2024, up 1131959.17% on a YoY basis from N/an in Q1 2024, and up 3.77% quarter-over-quarter from $4780.8 in Q2 2024.
Bright Minds Biosciences (DRUG) EPS (Weighted Average and Diluted) (2023 - 2024) Analysis & Trends
Bright Minds Biosciences has reported EPS (Weighted Average and Diluted) for 2 years, with the latest figure at $4961.0 in Q4 2024.
- For the quarter ending Q4 2024, EPS (Weighted Average and Diluted) rose 1131959.17% year-over-year to $4961.0; the trailing twelve-month figure through Jun 2025 stood at $0.01 (down 100.0% YoY), and the FY2024 full-year result was -$0.48, up 67.74% from the prior year.
- EPS (Weighted Average and Diluted) for Q4 2024 stood at $4961.0, up from $4780.8 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $4961.0 in Q4 2024, with the low at -$0.44 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 0.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -0.61 |
| 10 | Bright Minds Biosciences | 16.28 Bn | 16.22 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 4,961.00 |
| Jun 30, 2024 | 4,780.84 |
| Dec 31, 2023 | -0.44 |
| Jun 30, 2023 | -0.39 |